A Phase II Study of Preoperative Pembrolizumab for Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer Followed by Chemotherapy and Chemoradiation With Pembrolizumab
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2017
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary) ; Capecitabine
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 04 Oct 2017 Status changed from not yet recruiting to recruiting.
- 14 Sep 2017 Planned initiation date changed from 5 Sep 2017 to 5 Nov 2017.